

Congress of the United States

House of Representatives

SELECT SUBCOMMITTEE ON THE CORONAVIRUS PANDEMIC

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

Majority (202) 225-5074
Minority (202) 225-5051

November 21, 2024

Lawrence Tabak, D.D.S, Ph.D.
Principal Deputy Director
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892
[TRANSMITTED VIA EMAIL]

Dear Dr. Tabak:

Enclosed are post-hearing questions that have been directed to you and submitted to the official record for the Select Subcommittee on the Coronavirus Pandemic hearing that was held on Thursday, November 14, 2024, titled "Preparing for the Next Pandemic: Lessons Learned and The Path Forward."

To ensure a complete hearing record, please return your written response to the Committee on or before Thursday, December 5, 2024, including each question in full as well as the name of the member. Your response should be addressed to the Committee office at 2157 Rayburn House Office Building, Washington, D.C. 20515. Please also send an electronic version of your response by email to Marie Policastro, Clerk for the Select Subcommittee, at marie.policastro@mail.house.gov.

Thank you for your prompt attention to this request. If you need additional information or have other questions, please contact Committee on Oversight and Accountability staff at (202) 225-5074.

Sincerely,



Brad Wenstrup, D.P.M.
Chairman

cc: The Honorable Raul Ruiz, Ranking Member
Select Subcommittee on the Coronavirus Pandemic

**Questions for Dr. Lawrence Tabak
Principal Deputy Director
National Institutes for Health**

November 14, 2024: Select Subcommittee on the Coronavirus Pandemic hearing titled
“Preparing for the Next Pandemic: Lessons Learned and The Path Forward”

Questions from Rep. Michael Cloud

1. Both EcoHealth Alliance and Dr. Peter Daszak personally have now been debarred by HHS due to their failures to comply with NIH grant protocol.
 - a. How many individuals and organizations receiving NIH funding have been debarred in the past five years?
 - b. Does NIH maintain that this was an isolated incident as opposed to an indication of systemic failure?
 - c. Does this incident indicate that NIH’s oversight system failed in initially awarding the grant?
 - d. Does the fact that NIH waited to debar EcoHealth and Daszak until after this Subcommittee’s investigation of their failures to comply with NIH protocol became public indicate that NIH’s oversight system failed in allowing them to continue receiving funds until that point?
 - e. What improvements does NIH plan to implement to its grant award and oversight systems to ensure that this does not happen again?

2. Applications for NIH grants are reviewed by an Advisory Council or Board of the relevant Institute.
 - a. Are the names of the individuals who make this decision publicly disclosed?
 - b. Is any information on how they made their decision publicly disclosed?
 - c. Is there any way of holding these individuals accountable if they fail to exercise due diligence in reviewing these grant applications?

